| アブストラクト | BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors were introduced for the treatment of anaemia in chronic kidney disease (CKD) in Japan in 2020; however, data on their use in clinical practice remain limited. METHODS: This retrospective cohort study used data from the Medical Data Vision database to assess treatment patterns and hemoglobin trends in non-dialysis-dependent (NDD)-CKD anaemia. Cohort 1 included patients starting HIF-PH inhibitors or erythropoiesis-stimulating agents (ESAs) between 2021 and 2024, while Cohort 2 included patients who had received ESAs in 2020. Sub-cohort 1, patients with iron repletion status in Cohort 1, were also examined. RESULTS: Cohort 1 included 9,253 patients. The patients starting HIF-PH inhibitors increased annually from 15.1% in 2021 to 54.8% in the first quarter of 2024. In Sub-cohort 1, prescriptions of HIF-PH inhibitors also annually increased. In these cohorts, initiation with HIF-PH inhibitors showed trends to maintain higher hemoglobin levels than ESAs. In patients with functional iron deficiency, the reduction in proportion with Hb <10 g/dL was more pronounced in HIF-PH inhibitors than ESAs. Cohort 2 (n = 1,998) had a low annual switch rate from ESAs to HIF-PH inhibitors (2.4%-3.9%), and improvement of anaemia was observed in the switched patients in whom ESAs do not sufficiently correct anaemia. CONCLUSIONS: Real-world database analysis shows that initiation of HIF-PH inhibitors for renal anaemia in NDD-CKD increased to match that of ESAs by 2024, although switching from ESAs remained low. HIF-PH inhibitors showed a trend towards improvement in anaemia compared to ESAs, suggesting clinical benefit. |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| Pubmed追加日 | 2025/10/7 |
|---|
| 投稿者 | Ueta, Kiichiro; Ishii, Manabu; Oku, Akira; Arakawa, Kenji; Nishimura, Kenichi; Hashimoto, Toshio; Kuragano, Takahiro |
|---|
| 組織名 | Development & Medical Affairs Division, Mitsubishi Tanabe Pharma Corporation,;Tokyo, Japan.;Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo Medical;University, Nishinomiya, Hyogo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41055642/ |
|---|
